Positive News SentimentPositive NewsNASDAQ:SGMO Sangamo Therapeutics (SGMO) Stock Forecast, Price & News $1.15 +0.04 (+3.60%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$1.10▼$1.1650-Day Range$1.11▼$1.7652-Week Range$1.07▼$6.42Volume1.99 million shsAverage Volume2.41 million shsMarket Capitalization$197.60 millionP/E RatioN/ADividend YieldN/APrice Target$8.91 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Sangamo Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside675.2% Upside$8.91 Price TargetShort InterestHealthy10.25% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.77) to ($1.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector527th out of 983 stocksBiological Products, Except Diagnostic Industry87th out of 164 stocks 3.3 Analyst's Opinion Consensus RatingSangamo Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.91, Sangamo Therapeutics has a forecasted upside of 675.2% from its current price of $1.15.Amount of Analyst CoverageSangamo Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.25% of the outstanding shares of Sangamo Therapeutics have been sold short.Short Interest Ratio / Days to CoverSangamo Therapeutics has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Sangamo Therapeutics has recently decreased by 12.91%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSangamo Therapeutics does not currently pay a dividend.Dividend GrowthSangamo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SGMO. Previous Next 3.2 News and Social Media Coverage News SentimentSangamo Therapeutics has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Sangamo Therapeutics this week, compared to 2 articles on an average week.Search Interest24 people have searched for SGMO on MarketBeat in the last 30 days. This is an increase of 26% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Sangamo Therapeutics is held by insiders.Percentage Held by Institutions59.34% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sangamo Therapeutics are expected to decrease in the coming year, from ($0.77) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sangamo Therapeutics is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sangamo Therapeutics is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSangamo Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sangamo Therapeutics (NASDAQ:SGMO) StockSangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.Read More Receive SGMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SGMO Stock News HeadlinesMay 22, 2023 | finance.yahoo.comSangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry DiseaseMay 18, 2023 | finance.yahoo.comIndustry Analysts Just Upgraded Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Forecasts By 52%June 3, 2023 | Legacy Research (Affiliate) (Ad)The “Amazon Secret Royalty Program” Can Help Anyone Retire Like RoyaltyA unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.May 16, 2023 | finance.yahoo.comSangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical OfficerMay 14, 2023 | americanbankingnews.comAnalysts Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target at $9.07May 13, 2023 | americanbankingnews.comSangamo Therapeutics (NASDAQ:SGMO) Upgraded to Hold by StockNews.comMay 13, 2023 | americanbankingnews.comTruist Financial Trims Sangamo Therapeutics (NASDAQ:SGMO) Target Price to $8.00May 11, 2023 | msn.comTruist Securities Maintains Sangamo Therapeutics (SGMO) Buy RecommendationJune 3, 2023 | Legacy Research (Affiliate) (Ad)The “Amazon Secret Royalty Program” Can Help Anyone Retire Like RoyaltyA unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.May 2, 2023 | finance.yahoo.comSangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)May 2, 2023 | finance.yahoo.comAnalysts Just Made A Huge Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) ForecastsMay 2, 2023 | americanbankingnews.comSangamo Therapeutics (NASDAQ:SGMO) Given New $5.00 Price Target at HC WainwrightMay 1, 2023 | bizjournals.comSangamo Therapeutics chopping 120 jobs after Biogen, Novartis exit dealsMay 1, 2023 | msn.comSangamo Therapeutics's Return On Capital Employed OverviewMay 1, 2023 | msn.comHC Wainwright & Co. Maintains Sangamo Therapeutics (SGMO) Buy RecommendationMay 1, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Sangamo TherapeuticsApril 30, 2023 | americanbankingnews.comSangamo Therapeutics (NASDAQ:SGMO) Price Target Cut to $3.90 by Analysts at Stifel NicolausApril 29, 2023 | americanbankingnews.comSangamo Therapeutics (NASDAQ:SGMO) Rating Lowered to Underperform at Bank of AmericaApril 28, 2023 | msn.comB of A Securities Downgrades Sangamo Therapeutics (SGMO)April 27, 2023 | msn.comSoon After Novartis & Biogen Walked Away From Neurology Drug Partnerships, Sangamo Announces Major RestructuringApril 26, 2023 | finance.yahoo.comSangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial ResultsApril 25, 2023 | finance.yahoo.comBiogen shifts gene therapy focus as it builds $200M facility in RTPApril 25, 2023 | americanbankingnews.comSangamo Therapeutics (SGMO) to Release Earnings on WednesdayApril 21, 2023 | finance.yahoo.comStrength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?April 21, 2023 | finance.yahoo.comStrength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?April 19, 2023 | finance.yahoo.comSangamo Therapeutics Announces First Quarter 2023 Conference Call and WebcastApril 19, 2023 | americanbankingnews.comBrokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target at $12.80See More Headlines SGMO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SGMO Company Calendar Last Earnings2/22/2023Today6/03/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SGMO CUSIP80067710 CIK1001233 Webwww.sangamo.com Phone(510) 970-6000Fax510-236-8951Employees431Year Founded1995Price Target and Rating Average Stock Price Forecast$8.91 High Stock Price Forecast$16.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+675.2%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-192,280,000.00 Net Margins-52.76% Pretax Margin-52.53% Return on Equity-40.44% Return on Assets-22.97% Debt Debt-to-Equity RatioN/A Current Ratio3.93 Quick Ratio3.93 Sales & Book Value Annual Sales$111.30 million Price / Sales1.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.95 per share Price / Book0.59Miscellaneous Outstanding Shares171,830,000Free Float166,671,000Market Cap$197.60 million OptionableOptionable Beta1.07 Social Links Key ExecutivesAlexander D. MacraePresident, Chief Executive Officer & DirectorMark D. McClungChief Operating Officer & Executive Vice PresidentPrathyusha DurabaibuChief Financial & Accounting Officer, Senior VPR. Andrew RamelmeierExecutive Vice President-Technical OperationsJason D. FontenotChief Scientific Officer & Senior Vice PresidentKey CompetitorsCurisNASDAQ:CRISAgenusNASDAQ:AGENNovavaxNASDAQ:NVAXPoseida TherapeuticsNASDAQ:PSTXIkena OncologyNASDAQ:IKNAView All CompetitorsInsiders & InstitutionsGolden State Equity PartnersBought 135,765 shares on 6/1/2023Ownership: 0.079%Ameriprise Financial Inc.Sold 42,636 shares on 5/22/2023Ownership: 0.015%JPMorgan Chase & Co.Bought 11,863 shares on 5/18/2023Ownership: 0.916%New York State Common Retirement FundSold 40,123 shares on 5/18/2023Ownership: 0.023%Hudson Bay Capital Management LPBought 42,400 shares on 5/16/2023Ownership: 0.698%View All Insider TransactionsView All Institutional Transactions SGMO Stock - Frequently Asked Questions Should I buy or sell Sangamo Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SGMO shares. View SGMO analyst ratings or view top-rated stocks. What is Sangamo Therapeutics' stock price forecast for 2023? 5 analysts have issued twelve-month price objectives for Sangamo Therapeutics' shares. Their SGMO share price forecasts range from $1.50 to $16.00. On average, they predict the company's stock price to reach $8.91 in the next twelve months. This suggests a possible upside of 675.2% from the stock's current price. View analysts price targets for SGMO or view top-rated stocks among Wall Street analysts. How have SGMO shares performed in 2023? Sangamo Therapeutics' stock was trading at $3.14 at the beginning of the year. Since then, SGMO stock has decreased by 63.4% and is now trading at $1.15. View the best growth stocks for 2023 here. When is Sangamo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our SGMO earnings forecast. How were Sangamo Therapeutics' earnings last quarter? Sangamo Therapeutics, Inc. (NASDAQ:SGMO) announced its quarterly earnings results on Wednesday, February, 22nd. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.04. The biopharmaceutical company had revenue of $27.23 million for the quarter, compared to analyst estimates of $26.86 million. Sangamo Therapeutics had a negative trailing twelve-month return on equity of 40.44% and a negative net margin of 52.76%. The business's revenue was down 2.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.26) EPS. What ETFs hold Sangamo Therapeutics' stock? ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion mRNA ETF (MSGR), Global X Genomics & Biotechnology ETF (GNOM), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), WisdomTree BioRevolution Fund (WDNA), iShares Genomics Immunology and Healthcare ETF (IDNA) and SPDR S&P Biotech ETF (XBI). What guidance has Sangamo Therapeutics issued on next quarter's earnings? Sangamo Therapeutics updated its first quarter 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $158.00 million-$158.00 million. What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO? 10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees. What other stocks do shareholders of Sangamo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC). What is Sangamo Therapeutics' stock symbol? Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO." Who are Sangamo Therapeutics' major shareholders? Sangamo Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.22%), Wasatch Advisors LP (7.94%), State Street Corp (5.21%), Credit Suisse AG (2.23%), Dimensional Fund Advisors LP (1.92%) and Renaissance Technologies LLC (1.88%). Insiders that own company stock include Biogen Inc, Gary Loeb, John Markels, Rolf Andrew Ramelmeier and Saira Ramasastry. View institutional ownership trends. How do I buy shares of Sangamo Therapeutics? Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sangamo Therapeutics' stock price today? One share of SGMO stock can currently be purchased for approximately $1.15. How much money does Sangamo Therapeutics make? Sangamo Therapeutics (NASDAQ:SGMO) has a market capitalization of $197.60 million and generates $111.30 million in revenue each year. The biopharmaceutical company earns $-192,280,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. How many employees does Sangamo Therapeutics have? The company employs 431 workers across the globe. How can I contact Sangamo Therapeutics? Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The official website for the company is www.sangamo.com. The biopharmaceutical company can be reached via phone at (510) 970-6000, via email at investor.relations@sangamo.com, or via fax at 510-236-8951. This page (NASDAQ:SGMO) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.